公开(公告)号：US20080228151A1

公开(公告)日：2008-09-18

申请号：US12074259

申请日：2008-02-28

申请人： Jie Zhang ,  Kevin S. Warner ,  Randal Nelson ,  Alan Vawdrey ,  Nathan Strong ,  Suyi Niu ,  Michael D. Wessman ,  Matthew Iverson

发明人： Jie Zhang ,  Kevin S. Warner ,  Randal Nelson ,  Alan Vawdrey ,  Nathan Strong ,  Suyi Niu ,  Michael D. Wessman ,  Matthew Iverson

IPC分类号： A61F7/08 ,  A61K9/00 ,  A61K31/192 ,  A61K31/196 ,  A61K31/167

CPC分类号： A61K9/7061 ,  A61K9/0004 ,  A61K31/192

摘要： Systems and methods for transdermal drug delivery with controlled heat are provided. Such systems can comprise a heating apparatus that includes an exothermic chemical composition, typically in the form of individual heating elements. The heating apparatus can be exposed to ambient oxygen through a cover. The cover can reduce the amount of ambient oxygen capable of contacting the chemical composition compared to when the cover is not present. In some embodiments, the heating apparatus can include more than one heating element. The systems can further include a drug-containing layer that includes a drug. The drug-containing layer can have a surface area of about 50 cm2 to about 400 cm2. The systems of the present invention can be deliver ketoprofen in an amount sufficient to produce a mean blood plasma concentration of ketoprofen in a human subject of at least 45 ng/ml within four hours after initial application of the system to a skin surface.

摘要翻译： 提供了具有受控热的透皮药物递送的系统和方法。 这样的系统可以包括加热装置，其包括放热化学组成，通常为各个加热元件的形式。 加热装置可以通过盖子暴露于环境氧气。 与不存在盖时相比，盖可以减少能够接触化学成分的环境氧的量。 在一些实施例中，加热装置可以包括多于一个加热元件。 该系统可以进一步包括包含药物的含药层。 药物含有层可以具有约50cm 2至约400cm 2的表面积。 本发明的系统可以递送酮洛芬，其量足以在将该系统初次施用于皮肤表面后的四小时内在至少45ng / ml的人受试者中产生酮洛芬的平均血浆浓度。

公开(公告)号：US08907153B2

公开(公告)日：2014-12-09

申请号：US11146917

申请日：2005-06-06

申请人： Jie Zhang ,  Kevin S. Warner ,  Michael A. Ashburn ,  Larry D. Rigby ,  Suyi Niu

发明人： Jie Zhang ,  Kevin S. Warner ,  Michael A. Ashburn ,  Larry D. Rigby ,  Suyi Niu

IPC分类号： A61F13/00 ,  A61F13/02 ,  A61K9/70 ,  A61K9/14

CPC分类号： A61K9/7015 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/445 ,  A61K31/573 ,  A61K47/10 ,  A61K47/32

摘要： The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

摘要翻译： 本发明涉及用于药物真皮递送的粘合剂剥离形成制剂。 制剂可以包括药物，溶剂载体和剥离形成剂。 溶剂载体可以包括具有一种或多种挥发性溶剂的挥发性溶剂体系和具有一种或多种非挥发性溶剂的非挥发性溶剂体系，其中所述非挥发性溶剂体系对于在窗口内的药物具有溶解性 对药物具有可操作的溶解性，使得药物可以在持续的时间段内以治疗有效率递送。 在挥发性溶剂体系蒸发之前，配方可以具有适用于皮肤表面的粘度。 当施用于皮肤时，在挥发性溶剂体系的至少一部分蒸发之后，制剂可以形成固化的可剥离层。

公开(公告)号：US20050276842A1

公开(公告)日：2005-12-15

申请号：US11146917

申请日：2005-06-06

申请人： Jie Zhang ,  Kevin Warner ,  Michael Ashburn ,  Larry Rigby ,  Suyi Niu

发明人： Jie Zhang ,  Kevin Warner ,  Michael Ashburn ,  Larry Rigby ,  Suyi Niu

IPC分类号： A61K9/70

CPC分类号： A61K9/7015 ,  A61K31/167 ,  A61K31/192 ,  A61K31/196 ,  A61K31/445 ,  A61K31/573 ,  A61K47/10 ,  A61K47/32

摘要： The present invention is drawn to adhesive peel-forming formulations for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a peel-forming agent. The solvent vehicle can include a volatile solvent system having one or more volatile solvent, and a non-volatile solvent system having one or more non-volatile solvent, wherein the non-volatile solvent system has a solubility for the drug that is within a window of operable solubility for the drug such that the drug can be delivered at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified peelable layer after at least a portion of the volatile solvent system is evaporated.

摘要翻译： 本发明涉及用于药物真皮递送的粘合剂剥离形成制剂。 制剂可以包括药物，溶剂载体和剥离形成剂。 溶剂载体可以包括具有一种或多种挥发性溶剂的挥发性溶剂体系和具有一种或多种非挥发性溶剂的非挥发性溶剂体系，其中所述非挥发性溶剂体系对于在窗口内的药物具有溶解性 对药物具有可操作的溶解性，使得药物可以在持续的时间段内以治疗有效率递送。 在挥发性溶剂体系蒸发之前，配方可以具有适用于皮肤表面的粘度。 当施用于皮肤时，在挥发性溶剂体系的至少一部分蒸发之后，制剂可以形成固化的可剥离层。

公开(公告)号：US20120022158A1

公开(公告)日：2012-01-26

申请号：US13006780

申请日：2011-01-14

申请人： Suyi Niu ,  Wade A. Hull ,  Jie Zhang

发明人： Suyi Niu ,  Wade A. Hull ,  Jie Zhang

IPC分类号： A61K31/245 ,  A61P23/02

CPC分类号： A61K31/167 ,  A61K9/0014 ,  A61K31/136 ,  A61K47/32 ,  A61K2300/00

摘要： Solid-forming local anesthetic formulations for pain control can include a lidocaine base and tetracaine base, polyvinyl alcohol, water, and an emulsifier. The formulation can be prepared to be in a semi-solid state prior to application to a skin surface, can form a soft solidified layer after application, and can provide pain relief when applied to a skin surface proximate a pain site.

摘要翻译： 用于疼痛控制的固体形成局部麻醉剂制剂可以包括利多卡因碱和丁卡因碱，聚乙烯醇，水和乳化剂。 制剂可以在施用于皮肤表面之前制备成半固体状态，在施用后可以形成柔软的固化层，并且当施加到疼痛部位附近的皮肤表面时可以提供疼痛缓解。

公开(公告)号：US20050112068A1

公开(公告)日：2005-05-26

申请号：US10975766

申请日：2004-10-27

申请人： Kevin Warner ,  Michael Ashburn ,  Suyi Niu

发明人： Kevin Warner ,  Michael Ashburn ,  Suyi Niu

IPC分类号： A61F13/00 ,  A61K20060101 ,  A61K9/70 ,  A61K49/00

CPC分类号： A61K9/7023 ,  B09B3/0075 ,  B09B2220/14

摘要： The present invention is drawn to systems and methods for reducing unintended use of an active ingredient, such as residual active ingredients present in spent dermal patches and peels. The system can include a dermal patch including an active ingredient and a destructive agent configured to chemically react with the active ingredient. The destructive agent can be present in a container or an absorber. In one embodiment, the absorber can be used within the container. The container can be configured to receive the dermal patch such that the active ingredient contacts the destructive agent within the container. The absorber can be configured to contact the dermal patch such that the active ingredient contacts the destructive agent of the absorber. Additionally, systems and methods for impeding the unintended use of an active ingredient, such as those present in dermal patches or peels, are also provided. The system includes a dermal patch having a first side configured to deliver an active ingredient to a skin or mucosal surface, wherein the first side also includes a dermal adhesive. The system also includes an adhesive-coated device. The adhesive-coated surface of the device can be configured to adhere to the first side, wherein upon use of the dermal patch followed by contacting the adhesive-coated surface with the first side, residual active ingredient is rendered substantially inaccessible.

摘要翻译： 本发明涉及用于减少活性成分的非预期用途的系统和方法，所述活性成分例如存在于有效皮肤贴剂和皮肤中的残留活性成分。 该系统可以包括皮肤贴片，其包括配置成与活性成分发生化学反应的活性成分和破坏剂。 破坏剂可存在于容器或吸收器中。 在一个实施例中，吸收器可以在容器内使用。 容器可以被配置为接收皮肤贴片，使得活性成分与容器内的破坏剂接触。 吸收器可以被配置为接触皮肤贴片，使得活性成分与吸收体的破坏剂接触。 此外，还提供了用于阻止意图使用活性成分（例如存在于真皮贴剂或皮肤中的那些）的系统和方法。 该系统包括皮肤贴片，其具有构造成将活性成分递送至皮肤或粘膜表面的第一侧，其中第一面还包括真皮粘合剂。 该系统还包括涂有粘合剂的装置。 装置的粘合剂涂覆的表面可以被配置为粘附到第一侧，其中在使用皮肤贴片然后使粘合剂涂覆的表面与第一面接触时，残留的活性成分基本上不可接近。